Blood-based biomarkers and novel technologies for the diagnosis of colorectal cancer and adenomas: a narrative review.
Biomark Med
; 18(9): 493-506, 2024.
Article
de En
| MEDLINE
| ID: mdl-38900496
ABSTRACT
Aim:
Blood-based biomarkers have shown promise for diagnosing colorectal cancer (CRC) and adenomas (CRA). This review summarizes recent studies in this area.Methods:
A literature search was undertaken for 01/01/2017-01/03/2023. Criteria included CRC, CRA, liquid-biopsy, blood-based tests and diagnosis.Results:
12,378 studies were reduced to 178 for data extraction. Sixty focused on proteomics, 53 on RNA species, 30 on cfDNA methylation, seven on antigens and autoantibodies and 28 on novel techniques. 169 case control and nine cohort studies. Number of participants ranged 100-54,297, mean age 58.26. CRC sensitivity and specificity ranged 9.10-100% and 20.40-100%, respectively. CRA sensitivity and specificity ranged 8.00-95.70% and 4.00-97.00%, respectively.Conclusion:
Sensitive and specific blood-based tests exist for CRC and CRA. However, studies demonstrate heterogenous techniques and reporting quality. Further work should concentrate on validation and meta-analyzes.
[Box see text].
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs colorectales
/
Marqueurs biologiques tumoraux
/
Adénomes
Limites:
Humans
Langue:
En
Journal:
Biomark Med
Sujet du journal:
BIOQUIMICA
/
MEDICINA
Année:
2024
Type de document:
Article
Pays de publication:
Royaume-Uni